Search | Page 12 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

    ... PURPOSE: This international phase III, randomized, placebo -controlled, double-blind ... in RBC transfusion-dependent patients with International Prognostic Scoring System lower-risk non-del(5q) myelodysplastic ...

    Research Article last updated 07/18/2016 - 10:30am.

  2. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and po

    ... clinical and biological activity in patients with International Prognostic Scoring System (IPSS) lower-risk (low- and intermediate-1-risk) ...

    Research Article last updated 06/23/2016 - 10:17am.

  3. Integrating Frailty, Comorbidity, and Quality of Life in the Management of Myelodysplastic Syndromes

    ... intermediate-risk disease as classified by the Revised International Prognostic Scoring System (IPSS-R) or those with higher-risk disease for ...

    Research Article last updated 07/18/2016 - 11:26am.

  4. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.

    ... in the United States in 4 cohorts: (1) lower-risk MDS ( International Prognostic Scoring System [IPSS] low and intermediate-1 risk), with and ...

    Research Article last updated 09/19/2016 - 11:05am.

  5. Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the Europ

    ... conditioning and 34% and 27% had intermediate-2 and high international prognostic scoring system (IPSS) scores. At time of HSCT, 32% of patients ...

    Research Article last updated 07/18/2016 - 11:22am.

  6. Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis

    ... World Health Organization, French-American-British, or International Prognostic Scoring System (IPSS) criteria. Outcomes included erythroid ...

    Research Article last updated 06/23/2016 - 9:14am.

  7. Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study

    ... The median age was 73 years, and 79% had revised International Prognostic Scoring System (IPSS-R) risk scores of intermediate or lower. ...

    Research Article last updated 06/07/2016 - 11:03am.

  8. Personalized medicine for MDS

    ... determining therapy.  Key-Findings: -The International Prognostic Scoring System (IPSS) helps to risk stratify MDS patients into ...

    Research Review last updated 05/02/2016 - 9:44am.

  9. Myelodysplastic syndromes: Contemporary review and how we treat

    ... in MDS. Conventional prognostication is by the revised International prognostic scoring system (IPSS-R) with additional adverse prognosis ...

    Research Article last updated 04/29/2016 - 1:05pm.

  10. Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study

    ... We aimed to compare the ability of recently developed prognostic indices for myelodysplastic syndromes to identify patients ... (low and intermediate-1) categories defined by the International Prognosis Scoring System (IPSS). METHODS: We included ...

    Research Article last updated 04/29/2016 - 11:24am.